Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

A novel 3D bioprinted gastric cancer model using patient-derived tissues predicts drug responses, enhancing personalized ...

A collaborative research team from POSTECH has successfully developed a gastric cancer model using 3D bioprinting technology ...

Management trends and outcomes of appendiceal cancers: A National Cancer Database study. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...

Patients with non-metastatic GIST treated with neoadjuvant TKIs prior to surgery experienced a benefit which led to less ...

The British pharma giant plans to shell out $1 billion upfront to buy the drug developer working on a lead treatment for gastrointestinal stromal tumors. As the first morning of the J.P. Morgan ...

Taken together, the above findings suggest that tumor stroma is far from a passive bystander during tumor metastases. Tumor cells influence stromal changes including remodeling of the ECM ...

GSK has announced that it will be expanding its gastrointestinal (GI) cancer pipeline by acquiring IDRx in a deal ... being developed as a first- and second-line therapy for gastrointestinal stromal ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...